Recoded Arbovirus and Vaccines

Potential to create a novel class of live attenuated vaccines for dengue virus infections Background: Dengue virus (DENV) is an enveloped RNA arbovirus, primarily transmitted by a mosquito vector which has become widely distributed in tropical and subtropical regions. DENV infections are on of the leading anboviruses in the world. The diseases account for an estimated 50-200 million infections and 20,000 deaths. Currently, there are no marketable vaccines available capable of preventing human infection by DENV. One interesting feature of DENV is that it infects and replicates in two very different hosts, humans and mosquitoes. Professors at Stony Brook University are interested in leveraging differences found between humans and insects to produce a novel class of live attenuated dengue vaccines. Technology Overview: Dr. Eckard Wimmer, Professor at Stony Brook University has created a mathematical expression to calculate the codon-pair bias (CPB). It has been discovered that CPB diverges dramatically with increasing evolutionary distance such as between mammals and insects. In other words, bad pairs found in humans also do not work well in other mammals, and bad pairs found in certain insects also do not work well in other insects. Advantages: Ability to "tailor" the down-regulation of gene expression Will give added control and flexibility in arriving at an optimal formulation compared to currently used methods Applications: Creating a dengue vaccine Intellectual Property Summary: PCT Patent Filed Stage of Development: Licensing Potential: We seek to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area. Licensing Status: Available for License Additional Information: Dengue, Vaccine, Recoded, Colon Pair Bias, Humans ,
Patent Information:
Technology/Start-up ID: